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A B S T R A C T
Background: Despite the signiﬁcant socioeconomic burden associated with cardiac arrest (CA), data on CA pa-
tients’ long-term outcome and healthcare-associated costs are limited. The aim of this study was to determine
one-year survival, neurological outcome and healthcare-associated costs for ICU-treated CA patients.
Methods: This is a single-centre retrospective study on adult CA patients treated in Finnish tertiary hospital’s
ICUs between 2005 and 2013. Patients’ personal identiﬁcation number was used to crosslink data between
several nationwide databases in order to obtain data on one-year survival, neurological outcome, and health-
care-associated costs. Healthcare-associated costs were calculated for every patient stratiﬁed by cardiac arrest
location (OHCA=out-of-hospital cardiac arrest, IHCA= all in-hospital cardiac arrest, ICU-CA= in-ICU cardiac
arrest) and initial cardiac rhythm. Cost-eﬀectiveness was estimated by dividing total healthcare-associated costs
for all patients from the respective group by the number of survivors and survivors with favourable neurological
outcome.
Results: The study population included 1,024 ICU-treated CA patients. The sum of costs for all patients was
€50,847,540. At one-year after CA, 58% of OHCAs, 44% of IHCAs, and 39% of ICU-CAs were alive. Of one-year
survivors 97% of OHCAs, 88% of IHCAs, and 93% of ICU-CAs had favourable neurological outcome. Eﬀective
cost per one-year survivor was €76,212 for OHCAs, €144,168 for IHCAs, and €239,468 for ICU-CAs. Eﬀective
cost per one-year survivor with favourable neurological outcome was €81,196 for OHCAs, €164,442 for IHCAs,
and €257,207 for ICU-CAs.
Conclusions: In-ICU CA patients had the lowest one-year survival with the eﬀective cost per survivor three times
higher than for OHCAs.
Introduction
Cardiac arrest (CA) remains an important cause of morbidity and
mortality [1]. Despite numerous researches on CA, data on CA-related
healthcare costs are still scarce [2]. However, with an estimated
350,000–700,000 sudden CA events yearly in Europe alone, no doubt
exists that CA has signiﬁcant socioeconomic consequences [3,4]. Ac-
curate quantiﬁcation of cardiac arrest-related healthcare costs is im-
portant, as it can facilitate management and allocation of available
resources in order to improve post-CA outcomes through better pre-
vention and treatment strategies.
In this study, we determined one-year healthcare-associated costs
and outcomes in post-CA patients treated in intensive care units (ICU)
of a tertiary hospital, focusing on the impact of CA location and initial
cardiac rhythm on costs and outcomes.
Methods and materials
Setting and population
This retrospective study was conducted at Meilahti Hospital,
Helsinki, Finland, which serves as the primary referral centre for CA
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patients in the Helsinki and Uusimaa region, with a population of ap-
proximately 1.6 million people (30% of the total Finnish population).
Using the Finnish Intensive Care Consortium (FICC) database [5], we
identiﬁed adult CA patients (age ≥18 years) treated in Meilahti Hos-
pital’s ICUs from January 1, 2005, to December 31, 2013. Only the ﬁrst
cardiac arrest event was considered. Electronic health records (EHR) of
individual patients were reviewed for relevant data. Patients with
missing or incomplete data were excluded from the analyses. The study
was approved by the ethics committee of the Operative Division of
Helsinki University Hospital (June 2014: 194/13/03/02/2014 TMK02
§97), the Finnish National Institute for Health and Welfare (May 2014:
THL/713/5.05.01/2014), Statistics Finland (May 2014: TK-53-1047-
14), the Social Insurance Institution (September 2015: Kela 55/522/
2015) and the Oﬃce of the Data Protection Ombudsman (February
2016: 2794/204/2015).
Extracted variables and data sources
The FICC database provided data on hospital survival, preadmission
physical status (a modiﬁed World Health Organisation/Eastern
Cooperative Oncology Group [WHO/ECOG] classiﬁcation implemented
by FICC), mean daily Therapeutic Intervention Scoring System (TISS-
76) score and its components for the whole ICU stay, Simpliﬁed Acute
Physiology Score II (SAPS II) and Acute Physiology and Chronic Health
Evaluation II (APACHE II) components and scores [6–10]. To obtain the
conﬁrmed date of death, we linked the patients’ unique personal
identiﬁcation numbers with the Finnish Population Register Centre
database, which registers all deaths of Finnish residents. From the
hospital’s EHR, we gathered detailed information regarding time of CA,
time to return of spontaneous circulation (ROSC), initial cardiac
rhythm, CA location and cerebral performance category (CPC) for
survivors at one year after CA [11–13]. Good neurological outcome was
deﬁned as CPC scores 1–2, and poor neurological outcome as CPC
scores 3–4 [12,14].
Healthcare-associated costs
Total one-year healthcare-associated costs included three para-
meters: hospital costs, rehabilitation costs and social security costs.
Hospital costs were retrieved from the hospital’s billing records. These
costs were for the entire treatment period, including, e.g. personnel,
surgery, diagnostics, ICU stay, and ward stay. Rehabilitation costs were
calculated by multiplying the length of stay in the rehabilitation unit
with the average price per day for the respective level of care unit [15].
Social security costs were obtained from the national Social Insurance
Institution. All reimbursements made by the Social Insurance Institu-
tion, up to one-year after the admission, were obtained and summed.
These costs covered disability allowances, sickness allowances, private
physician and physiotherapist expenses, prescription drug expenses and
medical transport expenses.
Cost data analysis included calculation of mean healthcare costs for
hospital survivors, hospital non-survivors, one-year survivors and hos-
pital survivors who failed to survive to one year after CA. Mean costs
were calculated as the sum of total costs of the appropriate patient
group divided by the number of individuals in the same group. To es-
timate cost-eﬀectiveness, we calculated the eﬀective cost per survivor
(ECPS) and the eﬀective cost per survivor with favourable neurological
outcome (ECPFN). The ECPS and ECPFN were calculated as the sum of
total costs for all patients divided by the number of survivors and by the
number of survivors with favourable neurological outcome, respec-
tively [16].
We adjusted all costs according to the consumer price index (CPI) in
Finland to 2013 euros, using the following formula:
=CPI adjusted cost Cost CPI in
Admission year CPI
* 2013
Statistical analyses
For the statistical analyses, we used SPSS statistics for MAC, version
24.0, released 2016 (IBM Corp, Armonk, NY, USA) and Stata Statistical
Software for Mac OS (StataCorp LP, College Station, TX).
We used a chi-square test to compare categorical variables and a
Mann-Whitney U test or Student’s t-test for continuous data, as appro-
priate. To adjust for case-mix diﬀerences, we developed a severity-of-
illness model based on age, admission year, simpliﬁed preadmission
physical status (independent vs. non-independent), presence of a severe
comorbidity (according to SAPS II and APACHE II), initial cardiac
rhythm, time to ROSC and SAPS II score sum without age and co-
morbidity points. We used logistic regression to assess case-mix ad-
justed survival and neurological outcome stratiﬁed by CA location and
multivariate linear regression with CA location as a separate additional
variable to estimate the adjusted healthcare costs and treatment in-
tensity for the whole study population and separately for hospital sur-
vivors.
Results
Study population
A total of 1,024 patients were eligible for the study (mean 114
patients per year): 66% out-of-hospital cardiac arrests (OHCA) and 34%
in-hospital cardiac arrests (IHCA). Table 1 and Fig. 1 summarise the
exclusion process and baseline characteristics of the study population.
Compared to IHCA, OHCA patients were younger and had better
Table 1
Study population's baseline characteristics.
Variables OHCA
(n=672)
IHCA
(n= 352)
p-value
Age in years, median (IQR) 61 (53–69) 64 (56–74) < 0.05
Male gender, n (%) 514 (77) 231 (66) < 0.05
Simpliﬁed preadmission physical
statusa
independent, n (%) 637 (95) 296 (84) < 0.05
non-independent, n (%) 35 (5) 56 (16) < 0.05
Severe comorbidity at the time of ICU
admission, n (%)b
92 (14) 125 (36) < 0.05
SAPS II, median (IQR) 43 (34–57) 52 (39–68) < 0.05
APACHE II score, median (IQR) 21 (17–29) 27 (19–34) < 0.05
SOFA score during the ﬁrst 24 hours,
median (IQR)
8 (6–10) 10 (8–13) < 0.05
TISS-76 average daily score, mean
(SD)
37 (8) 36 (9) NS
Time to ROSC in minutes, median
(IQR)
20 (14–25) 7 (3–12) < 0.05
Initial cardiac rhythm
ventricular ﬁbrillation/ventricular
tachycardia, n (%)
504 (75) 116 (33) < 0.05
pulseless electrical activity 104 (15) 141 (40) < 0.05
asystole 49 (7) 66 (19) < 0.05
other/unknown 15 (2) 29 (8) < 0.05
LOS ICU in days, median (IQR) 3 (2–4) 3 (1–6) NS
LOS hospital in days, median (IQR) 10 (4–19) 10 (4–20) NS
One-year survival, n (%) 391 (58) 146 (41) –
One-year survivors with favourable
neurological outcome, n (%)
367 (97) 128 (88) –
OHCA=out-of-hospital cardiac arrest, IHCA= in-hospital cardiac arrest,
IQR= interquartile range, ICU= intensive care unit, SD= standard deviation,
SAPS= Simpliﬁed Acute Physiology Score, APACHE=Acute Physiology and
Chronic Health Evaluation, SOFA= Sequential Organ Failure Assessment, TISS-
76=Therapeutic Intervention Scoring System 76, ROSC= return of sponta-
neous circulation, LOS= length of stay.
a A simpliﬁed World Health Organization/Eastern Cooperative Oncology
Group classiﬁcation.
b Any severe chronic comorbidity according to APACHE II or SAPSII.
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physical status before ICU admission. Among IHCAs 67% experienced
cardiac arrest during the ﬁrst day of hospital admission. Compared to
OHCAs, IHCA patients had more severe comorbidities and were more
severely ill at the time of ICU admission. For the majority of OHCAs, the
initial cardiac rhythm was shockable, whereas the initial cardiac
rhythm was either pulseless electrical activity (PEA) or asystole (ASY)
for most of the IHCA cases. Time to ROSC was considerably longer for
OHCA patients (Table 1). Most of the excluded patients were from the
IHCA group, otherwise baseline characteristics between excluded and
included patients were similar (Supplementary material Table S1).
Outcomes
For OHCA patients, one-year survival was 58%; of these, 97% had
favourable neurological outcome. At one year after CA, 44% of IHCA
patients were alive, with favourable neurological outcome in 88% of
survivors. Our initial severity-of-illness model demonstrated fair pre-
dictive ability for both one-year survival (area under the receiver op-
erating characteristic curve [AUC], 0.78, 95% conﬁdence interval [CI],
0.76-0.81) and for favourable neurological outcome (AUC 0.73 [95%
CI, 0.65–0.82]).
Treatment intensity
Compared to OHCA, IHCA was associated with an increase in the
daily TISS-76 score of 1.9 points (95% CI, 0.7–3.2, p < 0.05). Non-
shockable rhythms and non-independent preadmission physical status
were associated with signiﬁcantly lower treatment intensity (Table S2).
Adjusted length of ICU stay was 1.2 days (95% CI 0.4–2.0) longer
for IHCAs, but there was no diﬀerence in adjusted length of hospital
stay between OHCA and IHCA. Neither initial cardiac rhythm nor time
to ROSC inﬂuenced the length of ICU stay. However, non-shockable
rhythms and prolonged time to ROSC were associated with signiﬁcantly
shorter length of hospital stay. Non-independent preadmission physical
status was associated with shorter length of ICU and hospital stays
(Tables S3 and S4). There was no signiﬁcant change in length of ICU or
hospital stay over the study period. For hospital survivors only, non-
shockable rhythms and non-independent preadmission physical status
were also associated with shorter length of hospital stay (Table S5).
Healthcare-associated costs
The sum of costs for all patients was €50,847,540. Of these, hospital
costs comprised 74%, rehabilitation costs 14% and social security costs
12%. Approximately €32 million (64% of total costs) were used for one-
year survivors with favourable neurological outcome. Mean total cost
per one-year survivor was €62,535 (95% CI, €58,009–€67,060) for
OHCA and €88,830 (95% CI, €73,108–€104,551) for IHCA. Mean total
cost for patients with favourable neurological outcome at one year was
€59,813 (95% CI, €55,514–€64,113) for OHCA and €81,796 (95% CI,
€69,535–€94,057) for IHCA. Mean total costs were markedly higher for
hospital and one-year survivors compared to non-survivors. Total costs
were lower for survivors with favourable neurological outcome than for
survivors with unfavourable outcome, irrespective of the location of CA
or the initial cardiac rhythm (Figs. 2 and 3).
Factors inﬂuencing healthcare-associated costs
Multivariate linear regression indicated that increasing age and in-
creased SAPS II score were associated with lower costs, although in-
creased SAPS II score had the opposite eﬀect on costs for hospital sur-
vivors (Tables 2 and S6). Severe preadmission comorbidity increased
total costs, along with hospital and social security costs. Preadmission
dependency on help in self-care did not inﬂuence healthcare costs.
Fig. 1. Patient selection ﬂowchart.
ICU= intensive care unit, CA= cardiac arrest, CPC=Cerebral Performance
Category, SAPSII= Simpliﬁed Acute Physiology Score II, ROSC= return of
spontaneous circulation, OHCA=out-of-hospital cardiac arrest, IHCA= in-
hospital cardiac arrest.
Fig. 2. Mean costs per patient stratiﬁed by cardiac arrest location.
OHCA=out-of-hospital cardiac arrest, IHCA= in-hospital cardiac arrest, ICU-CA= in-ICU cardiac arrest, CPC=Cerebral Performance Category. *Costs are ad-
justed to the consumer price index in Finland to 2013 euros.
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Compared to shockable rhythms, PEA had no signiﬁcant inﬂuence on
total costs or any of the cost components. Asystole reduced total costs
by a mean of €19,976 (95%CI €7,944–€32,008, p < 0.05) via reduc-
tion in hospital and social security costs, with a similar eﬀect for hos-
pital survivors (Tables 2 and S6). In comparison to OHCA, IHCA in-
creased total costs by a mean of €17,974 (95% CI €9,004€–€26,944,
p < 0.05). IHCA also increased hospital costs, but not rehabilitation or
social security costs (Table 2). Admission year did not inﬂuence
healthcare-associated costs.
Cost-eﬀectiveness
The ECPS was €94,688 and the ECPFN was €102,722, for all pa-
tients. For OHCA, ECPS was €76,212, and ECPFN was €81,196. For
IHCA, ECPS was €144,168, and ECPFN was €164,442. Both ECPS and
ECPFN were the highest for patients with PEA as the initial cardiac
rhythm (Fig. 4).
Subgroup analyses
Out of all IHCAs, 21% (75/352) had in-ICU cardiac arrest (ICU-CA)
and achieved ROSC. At one year after CA, 39% (29/75) of ICU-CA
patients were alive. Of these, 93% (27/29) had favourable neurological
outcome.
Treatment intensity was signiﬁcantly higher for ICU-CA patients
than for OHCA patients (Table S2). Both case-mix adjusted length of
ICU stay and case-mix adjusted length of hospital stay were sig-
niﬁcantly longer for ICU-CA patients than for OHCAs (Tables S3 and
S4).
For ICU-CA patients, the mean cost per one-year survivor was
€129,244 (95% CI €75,176–€183,311) and mean cost per one-year
survivor with favourable neurological outcome was €106,958 (95% CI
€74,863–€139,054). ICU-CA increased total costs signiﬁcantly for the
whole population and for hospital survivors (Tables 2 and S6). In the
ICU-CA group ECPS was €239,468 and ECPFN was €257,207.
Discussion
Key results
We determined one-year survival and neurological outcome along
with healthcare-associated costs for a tertiary hospital’s ICU-treated CA
patients. Patients with favourable neurological outcome consumed over
half of all costs. Eﬀective costs per survivor and per survivor with fa-
vourable neurological outcome were twice as high in the IHCA group
compared to OHCA, with the highest costs seen in the ICU-CA sub-
group. When stratiﬁed by the initial cardiac rhythm, the highest ECPS
and ECPFN were in the PEA group. Compared to shockable rhythms,
asystole was associated with a signiﬁcant decrease in total healthcare
costs, mainly due to reduction in hospital costs. Irrespective of the CA
location and the initial cardiac rhythm, the majority of one-year sur-
vivors achieved favourable neurological outcome.
Survival and neurological outcome
Previous studies have reported one-year survival rates for hospital-
treated OHCA between 27% and 55%, and for IHCA between 6% and
30% [17–23]. Over 80% of hospital survivors had favourable neuro-
logical outcome [24–30]. Compared to earlier publications, one-year
survival was generally higher in our study. Several factors can possibly
explain these diﬀerences in outcomes. Our study was conducted in a
densely populated urban area with high by-stander cardiopulmonary
resuscitation rates and eﬃcient emergency medical services (EMS) with
short CA-response times. Patients included in the study received post-
CA treatment in the ICUs of a tertiary hospital that serves as the primary
CA referral centre and has all established CA treatments and a wide set
of diagnostic procedures available around the clock. Additionally, our
study population consisted only of ICU-treated OHCA and IHCA pa-
tients, thus excluding patients who were denied ICU admission because
of failure to achieve ROSC or presumed poor outcome.
Healthcare-associated costs
Several publications reported CA-related healthcare costs pre-
viously. One of the ﬁrst studies on costs associated with the treatment of
OHCA reported total costs, including pre-hospital and in-hospital costs,
for a six-month survivor of €36,000 expressed in 2013 euros [17].
Several more recent studies reported hospital costs per patient between
€50,000 and €60,000 in 2013 euros for OHCA and IHCA hospital sur-
vivors, with costs per hospital survivor with favourable neurological
outcome between €17,000 and €80,000 in 2013 euros [2,19,31,32]. A
study by van Alem et al. reported healthcare-associated costs during the
ﬁrst half-year after OHCA, including prehospital, in-hospital and post-
hospital expenses, of €36,600 in 2013 euros [33]. Only one previous
Fig. 3. Mean costs per patient stratiﬁed by initial cardiac rhythm.
VF/VT= ventricular ﬁbrillation or ventricular tachycardia, PEA=pulseless electrical activity, ASY= asystole, CPC=Cerebral Performance Category. *Patients
with other or unknown initial cardiac rhythm excluded n= 44 (4%). **Costs are adjusted to the consumer price index in Finland to 2013 euros.
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study reported cost data for ICU-CA patients with ICU-related expenses
for hospital non-survivor of €54,000 in 2013 euros [34].
In comparison to previous studies, healthcare costs were higher in
the present study. Data on post-discharge expenses were limited and
only one of the previous studies reported healthcare-associated costs for
ICU-CA patients, a subgroup of the IHCA population that, according to
our study, consumes a considerable amount of resources for every
gained life and especially for a survivor with good neurological out-
come, suggesting a need to improve prevention and management
strategies also for ICU-CA.
Indeed, IHCA, and especially ICU-CA, was associated with sig-
niﬁcantly higher total healthcare costs compared to OHCA.
Table 2
Factors associated with healthcare costs based on multivariate linear regression.
Mean change in in costs per patient (€) 95%CI (€) p-value
Total costs
Agea −420 −671 −168 <0.05
Admission yearb 589 −728 1,906 NS
SAPSII scorec −351 −582 −119 <0.05
Severe comorbidity at the time of ICU admissiond 10,825 1,942 19,707 < 0.05
Preadmission physical status
Non-independent vs. independent −10,227 −22,840 2,386 NS
Time to ROSC (min)e −336 −723 51 NS
Initial cardiac rhythm, VF/VT as reference
PEA −4,808 −14,230 4,615 NS
Asystole −19,976 −32,008 −7,944 < 0.05
Location of cardiac arrest, OHCA as reference
all IHCA 17,974 9,005 26,944 < 0.05
ICU-CA 48,448 33,822 63,075 < 0.05
Hospital costs
Agea −164 −340 11 NS
Admission yearb 859 −61 1,778 NS
SAPSII scorec −204 −365 −42 <0.05
Severe comorbidity at the time of ICU admissiond 7,139 940 13,338 < 0.05
Preadmission physical status
Non-independent vs. independent −7,736 −16,538 1,067 NS
Time to ROSC (min)e −242 −512 28 NS
Initial cardiac rhythm, VF/VT as reference
PEA −5,297 −11,873 1,279 NS
Asystole −15,493 −23,891 −7,097 < 0.05
Location of cardiac arrest, OHCA as reference
all IHCA 14,320 8,060 20,581 < 0.05
ICU-CA 36,682 26,487 46,876 < 0.05
Rehabilitation costs
Agea −68 −174 39 NS
Admission yearb −315 −876 245 NS
SAPSII scorec −54 −152 44 NS
Severe comorbidity at the time of ICU admissiond 36 −3,739 3,810 NS
Preadmission physical status
Non-independent vs. independent −1,015 −6,374 4,344 NS
Time to ROSC (min)e −71 −235 94 NS
Initial cardiac rhythm, VF/VT as reference
PEA 1,439 −2,565 5,442 NS
Asystole −1,818 −6,930 3,295 NS
Location of cardiac arrest, OHCA as reference
all IHCA 3,255 −557 7,066 NS
ICU-CA 10,926 4,658 17,193 < 0.05
Social security costs
Agea −188 −235 −140 <0.05
Admission yearb 45 −203 295 NS
SAPSII scorec −93 −137 −49 <0.05
Severe comorbidity at the time of ICU admissiond 3,650 1,967 5,333 < 0.05
Preadmission physical status
Non-independent vs. independent −1,476 −3,866 914 NS
Time to ROSC (min)e −23 −97 50 NS
Initial cardiac rhythm, VF/VT as reference
PEA −949 −2,735 836 NS
Asystole −2,664 −4,944 −385 <0.05
Location of cardiac arrest, OHCA as reference
all IHCA 399 −1,300 2,099 NS
ICU-CA 841 −1,966 3,649 NS
CI= conﬁdence interval, OHCA=out-of-hospital cardiac arrest, IHCA= in-hospital cardiac arrest, ICU-CA= in-ICU cardiac arrest, ROSC= return of spontaneous
circulation, NS=not signiﬁcant, VF/VT= ventricular ﬁbrillation or ventricular tachycardia, PEA=pulseless electrical activity.
a For each additional year.
b For each subsequent year.
c For each additional point.
d Any severe chronic comorbidity according to APACHE II or SAPSII.
e For every additional minute.
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Interestingly, the observed increase in total costs for IHCA and ICU-CA
patients was mostly due to increase in hospital costs. The design of our
study does not allow for the establishment of any causative relationship
between costs and CA location.
Asystole was associated with lower treatment intensity and shorter
length of ICU and hospital stay, which possibly resulted in a signiﬁcant
reduction in total costs due to both reduced hospital and social security
costs for the whole study population and for hospital survivors only.
These ﬁndings suggest that CA patients with asystole as an initial
rhythm are likely to consume fewer resources, possibly due to the
higher risk of early mortality, diﬀerent aetiology of arrest and, in some
cases, an anticipated poor outcome and less active treatment approach.
The connection between consumed resources and PEA is less clear.
Increase in age and SAPS II score were associated with reduced total
healthcare-associated costs, due mostly to the reduction in hospital and
social security costs. One possible explanation could be the higher
mortality in elderly and more acutely ill patients. This is supported by
the inversed relationship between SAPS II score and healthcare-asso-
ciated costs for hospital survivors. However, age did not inﬂuence
treatment intensity or length of ICU and hospital stays, while an in-
crease in SAPS II score slightly reduced the TISS-76 score and length of
hospital stay but had no eﬀect on length of ICU stay.
Costs associated with care after critically ill patients, and especially
after comatose patients, are high and continue to increase [35–37]. In
ICU patients treated for acute renal failure, the mean cost for one six-
month survivor was €117,000 expressed in 2013 euros [38]. For criti-
cally ill cancer patients, costs per gained life were even higher [39]. For
patients with traumatic brain injury, overall eﬀective costs per one-year
survivor and one-year independent survivor were €47,708 and €75,595
respectively expressed in 2013 euros [16]. Chin-Yee et al. reported ICU
costs for very elderly (≥80 years) patients of €46,453 in 2013 euros
[40]. Considering these results, the eﬀective cost per one-year survivor
with favourable neurological outcome of €102,722 in our study does
not seem to be high and is lower than generally accepted incremental
cost-eﬀectiveness ratios [41].
Strengths and limitations
A major strength of the current study is that it was conducted in a
setting of government-funded healthcare with no selection bias due to,
e.g. socioeconomic factors and personal insurance. Thus, the study
provides a comprehensive and detailed evaluation of one-year survival
and healthcare-associated costs stratiﬁed by CA location with the case-
mix adjustment for CA-speciﬁc variables. Yet, one should be careful to
extrapolate our results to settings with very diﬀerent healthcare sys-
tems. Further, as the study’s population originates from a single tertiary
hospital with a highly eﬃcient local EMS, our results may not be gen-
eralisable on a global level.
Due to the retrospective nature of the study, the data are prone to
common information and misclassiﬁcation biases. We had to exclude
24% of patients from the analyses because of missing data. We were
unable to separate pre-arrest expenses from cardiac arrest-inﬂicted
expenses for IHCA and ICU-CA patients, which might lead to an over-
estimation of cardiac arrest-related costs. However, almost 70% of all
IHCA (ICU-CA included) patients experienced cardiac arrest during the
ﬁrst day of hospital stay. Due to the design of the study and the lim-
itations of the data sources, we also were unable to estimate CA-related
indirect societal costs, such as loss of work days, loss of national taxes,
and pension and life insurance pay-outs.
Conclusion
The lowest one-year survival of 39% was in ICU-CA patients.
Irrespective of the CA location, the vast majority of one-year survivors
had favourable neurological outcome, with ECPFN of €102,722. One-
year healthcare-associated eﬀective costs were twice as high for IHCA
patients compared to OHCA patients, and markedly higher in the PEA
group compared to other initial rhythms. Compared to OHCA, health-
care-associated costs were almost three times as high in ICU-CA pa-
tients. There is an undisputable need to improve prevention and man-
agement of IHCAs, especially those occurring in ICUs, to improve the
overall cost-eﬀectiveness of CA treatment.
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